Poseida Therapeutics Presented Case Study Demonstrating Reactivation Of CAR-T Therapy With A T-Cell Engager In A Patient With Relapsed Multiple Myeloma
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics presented a case study at the SOHO meeting, demonstrating the reactivation of their CAR-T therapy, P-BCMA-101, in a patient with relapsed multiple myeloma. This highlights the potential of their stem cell memory T cells (TSCM) in achieving a stringent complete response over three years after initial treatment.
September 04, 2024 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Poseida Therapeutics presented promising data on their CAR-T therapy, P-BCMA-101, showing potential long-term efficacy in relapsed multiple myeloma. This could enhance investor confidence in their CAR-T programs.
The presentation of successful reactivation of CAR-T therapy in a relapsed multiple myeloma patient suggests potential long-term efficacy of Poseida's CAR-T programs. This could positively influence investor sentiment and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90